MADRIGAL PHARMACEUTICALS, INC. · Exercise / conversion · Common Stock

What does this filing report?

An SEC Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. records an exercise / conversion involving Common Stock on November 13, 2025. The reported quantity was 6,000. The filing date is November 14, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.03 to $514.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.19 to $516.10, inclusive.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.15 to $518.10, inclusive.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.155 to $519.04, inclusive.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.18 to $520.15, inclusive.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.21 to $521.18, inclusive.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.22 to $522.21, inclusive.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $522.30 to $523.29, inclusive.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $523.31 to $524.29, inclusive.

F11

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $524.31 to $524.71, inclusive.

F12

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.17 to $527.09, inclusive.

F13

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.17 to $528.15, inclusive.

F14

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.18 to $528.94, inclusive.

F15

The shares underlying this option are fully vested and exercisable.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.